| Literature DB >> 30373468 |
Trishla Sinha1, Arnau Vich Vila1,2, Sanzhima Garmaeva1, Soesma A Jankipersadsing1,3, Floris Imhann1,2, Valerie Collij2, Marc Jan Bonder1, Xiaofang Jiang4,5, Thomas Gurry4,5, Eric J Alm4,5,6, Mauro D'Amato7,8, Rinse K Weersma2, Sicco Scherjon9, Cisca Wijmenga1,10, Jingyuan Fu1,3, Alexander Kurilshikov1, Alexandra Zhernakova1.
Abstract
Several gastrointestinal diseases show a sex imbalance, although the underlying (patho)physiological mechanisms behind this are not well understood. The gut microbiome may be involved in this process, forming a complex interaction with host immune system, sex hormones, medication and other environmental factors. Here we performed sex-specific analyses of fecal microbiota composition in 1135 individuals from a population-based cohort. The overall gut microbiome composition of females and males was significantly different (p = 0.001), with females showing a greater microbial diversity (p = 0.009). After correcting for the effects of intrinsic factors, smoking, diet and medications, female hormonal factors such as the use of oral contraceptives and undergoing an ovariectomy were associated with microbial species and pathways. Females had a higher richness of antibiotic-resistance genes, with the most notable being resistance to the lincosamide nucleotidyltransferase (LNU) gene family. The higher abundance of resistance genes is consistent with the greater prescription of the Macrolide-Lincosamide-Streptogramin classes of antibiotics to females. Furthermore, we observed an increased resistance to aminoglycosides in females with self-reported irritable bowel syndrome. These results throw light upon the effects of common medications that are differentially prescribed between sexes and highlight the importance of sex-specific analysis when studying the gut microbiome and resistome.Entities:
Keywords: female hormonal factors; gut microbiome; gut resistome; sex differences
Mesh:
Substances:
Year: 2018 PMID: 30373468 PMCID: PMC6546312 DOI: 10.1080/19490976.2018.1528822
Source DB: PubMed Journal: Gut Microbes ISSN: 1949-0976
Logistic regression of sex with antibiotic-resistance genes, gene families and resistance to antibiotic classes.
| ARO ID | Present in % of females | Present in % of males | Effect | p value | FDR | |
|---|---|---|---|---|---|---|
| ermF | ARO:3000498 | 37.13 | 28.33 | −0.41 | 0.002 | 0.080 |
| mel/msrD | ARO:3000616 | 48.23 | 39.96 | −0.34 | 0.005 | 0.080 |
| abeM (MATE) | ARO:3000753 | 44.38 | 37.42 | −0.30 | 0.015 | 0.080 |
| APH(3’’)-Ib | ARO:3002647 | 88.29 | 83.30 | −0.43 | 0.015 | 0.081 |
| lnuC/linC | ARO:3002837 | 85.21 | 78.44 | −0.47 | 0.003 | 0.081 |
| lmrC/ydaG | ARO:3002881 | 16.18 | 10.78 | −0.48 | 0.008 | 0.081 |
| lmrD/ydbA | ARO:3002882 | 24.96 | 18.60 | −0.38 | 0.010 | 0.081 |
| vanRD | ARO:3002923 | 8.32 | 4.65 | −0.66 | 0.013 | 0.081 |
| vanWG | ARO:3002965 | 38.06 | 30.23 | −0.36 | 0.006 | 0.081 |
| soxG/AcrAB | ARO:3003511 | 27.89 | 21.35 | −0.36 | 0.011 | 0.081 |
| MexJ | ARO:3003692 | 10.32 | 6.13 | −0.60 | 0.010 | 0.081 |
| glycopeptide gene cluster | 39.45 | 31.29 | −0.36 | 0.004 | 0.051 | |
| multidrug and toxic compount extrusion (MATE) | 46.53 | 38.90 | −0.33 | 0.007 | 0.061 | |
| ATP-binding cassette (ABC) AB efflux pump | 27.89 | 21.35 | −0.36 | 0.017 | 0.064 | |
| ESP beta-lactamase | 7.70 | 4.44 | −0.58 | 0.02 | 0.096 | |
| rifamycin-resistant (rpoB) | 20.96 | 16.28 | −0.34 | 0.03 | 0.096 | |
| lincosamide antibiotic | 89.37 | 84.14 | −0.45 | 0.011 | 0.055 | |
| Carbapenem | 12.79 | 8.03 | −0.51 | 0.014 | 0.055 | |
| Fluoroquinolone | 44.38 | 37.42 | −0.30 | 0.014 | 0.055 | |
| Glycopeptide antibiotic | 82.74 | 76.74 | −0.40 | 0.007 | 0.055 | |
| Sulfonamide antibiotic | 38.06 | 31.50 | −0.29 | 0.020 | 0.069 | |
| Peptide antibiotic | 20.96 | 16.28 | −0.34 | 0.032 | 0.069 | |
| Triclosan | 19.11 | 14.59 | −0.33 | 0.040 | 0.075 |
Logistic regression of self-reported IBS in females with antibiotic-resistance genes and resistance to antibiotic classes and mechanisms.
| ARO ID | Present in % of self-reported IBS | Present in % of non-IBS | Effect | p value | FDR | |
|---|---|---|---|---|---|---|
| APH(3’’)-Ib | ARO:3002639 | 29.89 | 10.85 | −1.32 | < 0.001 | < 0.001 |
| APH(6)-Id | ARO:3002660 | 36.78 | 15.48 | −1.20 | < 0.001 | < 0.001 |
| TolC | ARO:3000237 | 42.53 | 22.06 | −0.99 | < 0.001 | < 0.001 |
| MIR-9 | ARO:3002174 | 37.93 | 22.06 | −0.80 | 0.001 | 0.012 |
| aad(6) | ARO:3002628 | 59.77 | 41.28 | −0.79 | 0.0008 | 0.012 |
| vanRD | ARO:3002923 | 17.24 | 6.94 | −1.09 | 0.001 | 0.013 |
| msrB | ARO:3002818 | 37.93 | 22.42 | −0.79 | 0.001 | 0.013 |
| emrA | ARO:3000027 | 22.42 | 12.63 | −0.88 | 0.001 | 0.013 |
| APH(6) | 36.78 | 15.48 | −1.20 | < 0.001 | < 0.001 | |
| ATP-binding cassette (ABC) AB efflux pump | 45.98 | 26.16 | −0.91 | < 0.001 | 0.001 | |
| MIR beta-lactamase | 37.93 | 22.06 | −0.80 | 0.001 | 0.011 | |
| ANT(3”) | 20.69 | 9.96 | −0.85 | 0.004 | 0.033 | |
| quinolone resistance protein (qnr) | 22.99 | 13.88 | −0.79 | 0.006 | 0.044 | |
| Macrolide AB; tetracycline | 42.53 | 22.06 | −0.99 | < 0.001 | < 0.001 | |
| Macrolide AB; streptogramin | 74.71 | 56.76 | −0.84 | 0.001 | 0.008 | |
| Monobactam | 37.93 | 22.06 | −0.80 | 0.001 | 0.008 | |
| Fluoroquinolone; cephalosporin | 35.63 | 21.35 | −0.75 | 0.002 | 0.013 | |
| Fluoroquinolone; lincosamide | 37.93 | 25.44 | −0.62 | 0.010 | 0.045 |